PMID- 8954062
OWN - NLM
STAT- MEDLINE
DCOM- 19970106
LR  - 20221207
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 81
IP  - 12
DP  - 1996 Dec
TI  - Lack of an association between alleles of interleukin-1 alpha and interleukin-1 
      receptor antagonist genes and Graves' disease in a North American Caucasian 
      population.
PG  - 4476-8
AB  - Although an association between the human leukocyte antigen (HLA) allele DR3 and 
      Graves' disease (GD) is well documented, the potential role of non-HLA-linked 
      alleles in susceptibility to GD is an area of active investigation. In an attempt 
      to study the potential role of two non-HLA susceptibility alleles in GD and 
      Graves' ophthalmopathy, we examined 286 North American Caucasian individuals (145 
      normal controls and 141 individuals with GD) for the presence of the A2 allele of 
      the interleukin-1 (IL-1) receptor antagonist gene. In addition, we examined a 
      subset of this population (83 normal controls and 89 individuals with GD) for a 
      specific polymorphism within exon 5 of the IL-1 alpha gene. We found the A2 
      allelic frequencies (0.25 and 0.23, respectively) and carriage rates (43% and 
      41%, respectively) in the two groups to be nearly identical. However, findings in 
      the subgroup of patients with the extrathyroidal manifestations of GD (Graves' 
      ophthalmopathy, pretibial dermopathy, and acropachy) suggested a trend toward a 
      higher prevalence of the A2 allele in patients with more severe disease. The 
      allelic frequency (0.28) and carriage rate (47%) of the IL-1 alpha exon 5 
      polymorphism in individuals with GD were nearly identical to those of the control 
      population (0.28% and 45%, respectively). In summary, we were unable to 
      demonstrate an association between these alleles and GD in our study population. 
      We conclude that neither the A2 allele of the IL-1 receptor antagonist gene nor 
      the IL-1 alpha exon 5 polymorphism confers increased susceptibility to GD.
FAU - Cuddihy, R M
AU  - Cuddihy RM
AD  - Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Bahn, R S
AU  - Bahn RS
LA  - eng
GR  - EY-08819/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (IL1RN protein, human)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Interleukin-1)
RN  - 0 (Sialoglycoproteins)
SB  - IM
MH  - *Alleles
MH  - Female
MH  - Graves Disease/*genetics
MH  - Heterozygote
MH  - Humans
MH  - Interleukin 1 Receptor Antagonist Protein
MH  - Interleukin-1/*genetics
MH  - Male
MH  - Sialoglycoproteins/*genetics
MH  - White People
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1210/jcem.81.12.8954062 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1996 Dec;81(12):4476-8. doi: 10.1210/jcem.81.12.8954062.